We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Reduction of Oncogene Activity Causes Cancer Cells to Revert to Normal

By Biotechdaily staff writers
Posted on 09 Jul 2008
Cancer researchers working with a mouse model have found that by reducing the activity of the Myc oncogene, they could reverse the uncontrolled growth of cancer cells and return them to a normal, healthy state.

All normal cells require Myc activity. More...
However, Myc overexpression causes cells to grow too large and multiply uncontrollably. Previous studies have shown that eliminating Myc caused the death of tumor cells but had the same effect on normal tissues.

In the current study investigators at Stanford University (Palo Alto, CA, USA) worked with mice that had been genetically engineered to develop Myc-driven tumors in response to a chemical in their drinking water. After triggering tumor development at high levels of Myc activity, they gradually reduced the level of Myc. During this process they monitored both the genomic - oligonucleotide microarray analysis and quantitative PCR were used to identify changes in expression in 3,921 genes – and proteomic status of the cells. In the latter case, two-dimensional protein analysis followed by mass spectrometry, phospho-flow fluorescence-activated cell sorting, and antibody arrays were employed.

Results published in the July 1, 2008, issue of the journal Cancer Research revealed that as the Myc concentration reached the critical level where cancer cells began to revert to normal 2,348 genes were down-regulated while 1,573 were up-regulated, and proteins involved in mRNA translation decreased. In short, at the MYC threshold level, there was a loss of the oncogene's ability to maintain tumorigenesis, with associated shifts in gene and protein expression that reestablished cell cycle checkpoints, halted protein translation, and promoted apoptosis.

"In the past, scientists have shown that cancer signals such as Myc are like light switches,” said senior author Dr. Dean Felsher, associate professor of oncology and pathology at Stanford University. "Now we know that, in some cases, you do not need to turn the light completely off. We were able to experimentally prove that we can turn Myc off a little bit, or for a little time, and that is enough to have a profound effect on cancer.”


Related Links:
Stanford University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.